{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:33Z","timestamp":1761823533419,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":3050,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Visceral Surgery"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jviscsurg.2012.10.018","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T07:46:33Z","timestamp":1353656793000},"page":"60-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hyperthermic isolated liver perfusion with melphalan and bevacizumab"],"prefix":"10.1016","volume":"150","author":[{"given":"T.","family":"Voron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zinzindohou\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Journois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Herv\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ponzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0016-5085(90)90296-D","article-title":"Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis","volume":"98","author":"Franco","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0010","first-page":"511","article-title":"Hepatic resection for hepatocellular carcinoma","volume":"107","author":"Tsuzuki","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0015","first-page":"752","article-title":"Liver transplantation for the treatment of hepatocellular carcinoma","volume":"25","author":"Hanish","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0020","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00432-011-1026-9","article-title":"Interventional therapies of unresectable liver metastases","volume":"137","author":"Qian","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00316981","article-title":"Resection of colorectal liver metastases","volume":"19","author":"Scheele","year":"1995","journal-title":"World J Surg"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1046\/j.1365-2168.1999.01030.x","article-title":"Factors influencing survival of patients undergoing hepatectomy for colorectal metastases","volume":"86","author":"Yamamoto","year":"1999","journal-title":"Br J Surg"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0035","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I","article-title":"Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie","volume":"77","author":"Nordlinger","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjsurg.2003.04.007","article-title":"Management of neuroendocrine liver metastases","volume":"187","author":"Sutcliffe","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4254\/wjh.v3.i1.8","article-title":"Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future","volume":"3","author":"Kunzli","year":"2011","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0050","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2005.12.039","article-title":"Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study","volume":"23","author":"Berber","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0055","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1148\/radiol.2211001624","article-title":"Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients","volume":"221","author":"Solbiati","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/jnci\/88.12.838-a","article-title":"Re: Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer","volume":"88","author":"Anand","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0065","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1200\/JCO.2007.12.1764","article-title":"Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?","volume":"25","author":"Mocellin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0240","first-page":"CD007823","article-title":"Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer","volume":"3","author":"Mocellin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0075","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-008-9881-6","article-title":"Isolated hepatic perfusion with 200mg melphalan for advanced noncolorectal liver metastases","volume":"15","author":"van Iersel","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0080","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/annonc\/mdp589","article-title":"Management of isolated non-resectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy","volume":"21","author":"van Iersel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1245\/s10434-009-0482-9","article-title":"Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center","volume":"16","author":"Alexander","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1245\/s10434-008-0179-5","article-title":"A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer","volume":"16","author":"Zeh","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0197-2456(95)00078-X","article-title":"Biological rationale and clinical experience with hyperthermia","volume":"17","author":"Engin","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0100","first-page":"317","article-title":"Interactions of hyperthermia and drugs: treatments and probes","volume":"61","author":"Hahn","year":"1982","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0105","first-page":"2010","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN","author":"Ferlay","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-002-0503-x","article-title":"Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)","volume":"50","author":"Boucher","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/annonc\/mdf079","article-title":"Oral eniluracil\/5-fluorouracil in patients with inoperable hepatocellular carcinoma","volume":"13","author":"Benson","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0120","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/S0959-8049(97)00163-9","article-title":"Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study","volume":"33","author":"Bobbio-Pallavicini","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/0973-1482.92023","article-title":"An overview of evidence-based management of hepatocellular carcinoma: A meta-analysis","volume":"7","author":"Salhab","year":"2011","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial, Groupe CHC","volume":"29","author":"Pelletier","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0245","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","author":"Groupe d\u2019\u00e9tude et de traitement du carcinome hepatocellulaire","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0155","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0160","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000065059","article-title":"Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma","volume":"62","author":"Sangro","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0170","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000227477","article-title":"The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma","volume":"52","author":"Toyoda","year":"1995","journal-title":"Oncology"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11605-007-0089-z","article-title":"Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned","volume":"11","author":"Bloomston","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0180","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0185","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0195","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0200","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","article-title":"Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms","volume":"136","author":"Grover","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0205","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1245\/s10434-006-9108-7","article-title":"Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease","volume":"14","author":"Mocellin","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0210","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdn032","article-title":"Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients","volume":"19","author":"van Iersel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/ejso.2002.1328","article-title":"Isolated liver perfusion for non-resectable liver tumours: a review","volume":"28","author":"Christoforidis","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.sla.0000103133.03688.3d","article-title":"Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma","volume":"239","author":"Ku","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0225","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1245\/ASO.2004.09.021","article-title":"Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study","volume":"11","author":"van Etten","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0230","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","article-title":"Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies","volume":"23","author":"Pingpank","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jviscsurg.2012.10.018_bib0235","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1245\/s10434-007-9714-z","article-title":"Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion","volume":"15","author":"Verhoef","year":"2008","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Visceral Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788612001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878788612001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:29:27Z","timestamp":1761809367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878788612001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1878788612001191"],"URL":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2012.10.018","relation":{},"ISSN":["1878-7886"],"issn-type":[{"type":"print","value":"1878-7886"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic isolated liver perfusion with melphalan and bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Visceral Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviscsurg.2012.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}